Can a different immune drug cut viral infections after stem cell transplants?
NCT ID NCT06895538
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether a drug called ATLG, used before a stem cell transplant, can help the immune system recover better and reduce viral infections compared to the standard drug ATG. The study involves adults with blood cancers like leukemia, lymphoma, or MDS who are receiving their first transplant. Participants will get either ATLG or ATG as part of their conditioning regimen, and researchers will track immune recovery and infection rates afterward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)
- What this could lead to
- If ATLG works better than the standard ATG, it could lower the risk of serious viral infections and improve immune recovery after stem cell transplants, making the procedure safer for people with blood cancers.
- What could go wrong
- This is an early-stage, small study (24 participants) and not randomized, so results may not be conclusive. ATLG may not prove superior to ATG, and both drugs carry risks like increased infection or immune complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Frailty check may steer safer cancer care for seniors
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?